The S&P/ASX 200 Index (ASX: XJO) is down 0.4% today, despite the best efforts of ASX 200 share Ansell Ltd (ASX: ANN).
Shares in the health and safety products company closed Friday at $34.93. In morning trade on Monday, they are changing hands for $37.29, up 6.8%. That brings the Ansell share price up almost 55% since this time last year.
Here's what's spurring interest in the ASX 200 share today.
(*Note: All figures below in US dollars unless otherwise stated.)
ASX 200 share rockets on surging earnings
Investors are bidding up the Ansell share price today on the back of the company's half-year results for the six months to 31 December (H1 FY 2025).
Highlights included a 12.5% year on year increase in sales on an organic constant currency-basis to $1.02 billion. On a reported-basis, sales increased by 29.9%.
Breaking that down, the ASX 200 share reported industrial segment organic constant currency sales growth of 8.1%, and its healthcare segment organic constant currency sales growth was 16.3%.
Ansell also reported strong earnings growth, with earnings before interest and taxes (EBIT) of $127 million, up 20.9% from H1 FY 2024 on an organic constant currency-basis. On a reported-basis, EBIT increased 62.9%.
Ansell's industrial segment achieved organic constant currency EBIT growth of 12.2%, while the ASX 200 share's healthcare segment reported organic constant currency EBIT growth of 30.0%.
And the EBIT margin increased to 12.5% from 10.0% in H1 FY 2024.
Operating cash flow of $53.5 million was down 7.6% year on year.
The company also rewarded passive income investors with an unfranked interim dividend of 22.0 US cents per share, which reflects a payout ratio of 40%.
Among the major achievements of the half year, Ansell completed its acquisition of KBU on 1 July.
What did management say?
Commenting on the strong half-year results sending the ASX 200 share soaring today, Ansell CEO Neil Salmon said, "I am encouraged by the momentum in our underlying business and pleased that we are on track to complete the complex integration of KBU within twelve months while continuing to deliver our productivity program (APIP) objectives."
Salmon added:
Good top and bottom-line results in our Industrial Segment were supported by a significant contribution from new products, helping to overcome muted demand conditions in key manufacturing end markets, and our Healthcare Segment rebounded from the effects of distributor destocking in the prior period.
Higher sales drove strong earnings growth in both segments, including a contribution from KBU which was ahead of our acquisition business case, and growing savings from APIP.
What's ahead for the ASX 200 share?
Looking at what could impact the ASX 200 share in the months ahead, Salmon said:
Entering the second half we see a path to continued organic constant currency1 sales growth, despite subdued industrial demand and uncertainty stemming from changing trade policies in various countries, underpinned by the opportunity and flexibility provided by Ansell's balanced end market exposure and diversified global supply chain.
On the back of a strong first half, Ansell increased its full-year FY 2025 adjusted earnings per share (EPS) guidance range to US$1.18 to US$1.28 per share.
H1 FY 2025 adjusted EPS came in at 55.7 US cents per share.
